Oncology/Hematology: market research reports

... are today 103 companies plus partners developing 109 Wnt pathway targeting drugs in 385 developmental projects in cancer. In addition, there is 1 suspended drug and the accumulated number of ceased drugs over the last ...  |  read more...

... the research and development, a history of the achievements up to date, and a guide pointing out the directions of the future. The product as well, lays the framework of current treatment strategies and their ...  |  read more...

... the research and development, a history of the achievements up to date, and a guide pointing out the directions of the future. The product as well, lays the framework of current treatment strategies and their ...  |  read more...

... map of the research and development, a history of the achievements up to date, and a guide pointing out the directions of the future. The product as well, lays the framework of current treatment strategies ...  |  read more...

... elusive, leaving the market wide open. There are today 223 companies plus partners developing 255 cancer vaccine drugs in 538 developmental projects in cancer. In addition, there are 7 suspended drugs and the accumulated number ...  |  read more...

... for the cell trafficking and thus are vital for protective host response. In addition, chemokines regulate plethora of biological processes of hematopoietic cells to lead cellular activation, differentiation and survival. There are today 151 companies ...  |  read more...

... and metastatic setting, the overall survival remains below five years. There are today 359 companies plus partners developing 497 drugs targeting breast cancer in development. In addition, there are 9 suspended drugs and the accumulated ...  |  read more...

... for Uterine Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Uterine Cancer. Uterine Cancer - Pipeline Review, Half Year ...  |  read more...

... in the bone marrow that invade the blood and potentially other organs, depending on the phase of the cancer (ACS, 2012; NLM, 2012). Based on clinical characteristics and laboratory findings, CML is divided into three ...  |  read more...

... complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Sarcomas. Sarcomas - Pipeline Review, Half Year is built using data and ...  |  read more...

... for Ovarian Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Ovarian Cancer. Ovarian Cancer - Pipeline Review, Half Year ...  |  read more...

... for T-Cell Lymphomas, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for T-Cell Lymphomas. T-Cell Lymphomas - Pipeline Review, Half Year ...  |  read more...

... therapeutic development for Squamous Cell Carcinoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Squamous Cell Carcinoma. Squamous Cell Carcinoma ...  |  read more...